

6th of October, 2017

To,

1. Gilead Sciences, Inc.

333 Lakeside Drive, Foster City
California 94404, USA

2. Medicines Patent Pool

Chemin Louis-Dunant 17
1202 Geneva, Switzerland

Subject: Termination of License granted for APIs - Cobicistat (COBI), Elvitegravir (EVG), and Tenofovir Disoproxil Fumarate (TDF).

Reference: License Agreement dated 3rd of July, 2017 (Appendix 6-B for New Licenses in India) ("License Agreement"), executed by and between Gilead Sciences, Inc., the Medicines Patent Pool and Dr. Reddy's Laboratories Limited ("Dr. Reddy's").

Dear Sir/Madam,

In accordance with section 10.5 of the above License Agreement, Dr. Reddy's hereby provides notice of termination of the license for APIs - Cobicistat (COBI), Elvitegravir (EVG), and Tenofovir Disoproxil Fumarate (TDF), effective immediately as of the date of this letter.

We look forward to a fruitful and collaborative relationship with Gilead Science and the Medicines Patent Pool.

Yours Sincerely,



Deepak Sapra

Vice President & Global Head - Custom Pharmaceutical Services Business